Investors should monitor the full Phase 2 OCU410 data in March 2026 and upcoming clinical milestones as potential catalysts. The cash runway remains tight, but dilution risk may be mitigated if Janus Henderson warrants are exercised. Positive data could drive re-rating despite current losses.
Price Chart
Executive Summary
Ocugen reported Q4 and full-year 2025 financial results showing increased R&D spending and a wider net loss, while highlighting clinical progress across its gene therapy pipeline, including completed Phase 3 enrollment for OCU400 and positive preliminary Phase 2 data for OCU410 in geographic atrophy. The company extended its cash runway into Q4 2026 via a $22.5M financing, with potential extension to Q2 2027 if warrants are exercised.
Key Financial Metrics
Key Facts
- Completed enrollment in OCU400 Phase 3 trial for retinitis pigmentosa; topline data expected Q1 2027.
- Positive preliminary Phase 2 data for OCU410 in geographic atrophy: 46% lesion growth reduction (p=0.015), 50% responder rate with >50% reduction.
- OCU410ST Phase 2/3 trial for Stargardt disease nearing enrollment completion; interim data expected Q3 2026.
- Secured $22.5M in gross proceeds in January 2026; cash runway extended to Q4 2026, potentially Q2 2027 with full warrant exercise.
- Cash and restricted cash: $18.9M as of Dec 31, 2025, down from $58.8M a year prior.
- Net loss per share increased to $0.06 (Q4) and $0.23 (full year) from $0.05 and $0.20 respectively in 2024.
Financial Impact
Revenue declined to -$193K in Q4 2025 from $764K in Q4 2024; full-year revenue increased slightly to $4.4M. Net loss widened to $67.8M in 2025 from $54.1M in 2024. R&D expenses rose to $39.8M from $32.1M.
Risk Factors
- Clinical trial results may not meet expectations, particularly in Phase 3 for OCU400 and upcoming OCU410 readouts.
- Cash runway remains limited; additional financing may lead to further dilution.
- No revenue from product sales; company remains pre-commercial with high R&D burn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249353 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | Press Release | $1.33 $1.05 | ▼ −21.05% | ▼ −22.23% | $1.02 (−23.31%) |
Jul 13, 2026 11w ago | 8-K | $1.41 $1.31 | ▼ −7.09% | ▼ −10.28% | $1.02 (−27.66%) |
Jun 11, 2026 16w ago | 8-K | $1.21 $1.47 | ▲ +21.49% | ▲ +19.71% | $1.02 (−15.70%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.22 $1.47 | ▲ +20.49% | ▲ +18.60% | $1.02 (−16.39%) |
May 5, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▲ +10.07% | ▲ +15.02% | $1.02 (+31.54%) |
May 4, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
Apr 29, 2026 22w ago | Press Release | $1.68 $1.38 | ▼ −17.86% | ▼ −23.32% | $1.02 (−39.29%) |
Mar 24, 2026 27w ago | Press Release | $1.92 $1.68 | ▼ −12.50% | ▼ −21.40% | $1.02 (−46.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access